# Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

> **NCT00235053** · PHASE4 · COMPLETED · sponsor: **Allergy & Asthma Medical Group & Research Center** · enrollment: 13 (—)

## Conditions studied

- Asthma
- Candidiasis, Oral
- Voice Disorders

## Interventions

- **DRUG:** fluticasone/salmeterol DISKUS 250/50

## Key facts

- **NCT ID:** NCT00235053
- **Lead sponsor:** Allergy & Asthma Medical Group & Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 13 (—)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00235053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00235053, "Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00235053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*